moneyheap
ASH · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Ashland Inc. (ASH) stock moving?
Ashland closed at $76.81 on Nov 10, down about 1.2% from $77.70 on Nov 9 and well above its 30-day low of $71.00 on Oct 22. The stock rallied from about $73 after the Nov 3 Q4 report, which missed on adjusted EPS ($1.12 vs $1.27 estimated) and sales ($498M vs $501.8M), but the company guided fiscal 2027 sales to $1.905B-$1.975B and adjusted EBITDA to $405M-$435M. The sales guidance midpoint sits slightly above the $1.929B consensus, and management highlighted growth in Life Sciences and Personal Care. Volume rose sharply from Nov 3 to Nov 6, peaking at 1.70M shares on the $79.50 intraday high, which points to heavy trading interest. Analyst sentiment turned more constructive after earnings: JP Morgan raised its target to $82 (Overweight), Wells Fargo raised its target to $80 (Equal-Weight), and UBS raised its target to $88 (Buy). Takeover headlines add two-sided uncertainty: Bloomberg reported Evonik is cooling on a potential bid, while Handelsblatt reports Evonik rejected a BASF takeover approach after initial direct talks. These reports are unconfirmed and could change quickly. The stock trades about 8% below the average of the three new targets.
News behind the analysis
- Wells Fargo Maintains Equal-Weight on Ashland, Raises Price Target to $80Wells Fargo kept its equal-weight rating and raised its price target to $80 from $75.
- Evonik Rejects BASF Takeover Approach Even After First Direct Talks: HandelsblattHandelsblatt reports that Evonik rejected a BASF takeover approach even after first direct talks between the companies.
- Evonik, BASF CEOs & CFOs Met Saturday Near Frankfurt; Evonik Treated It As Purely Informational, Stressed Wish To Stay Independent: HandelsblattPer Handelsblatt, the CEOs and CFOs of Evonik and BASF met near Frankfurt, and Evonik treated the meeting as purely informational while stressing its wish to stay independent.
- Wells Fargo Analyst Adjusts Ashland Price TargetWells Fargo analyst Abigail Eberts kept a Hold rating and raised the price target from $75 to $80.
- Evonik Cooling on Bid for Ashland, Bloomberg ReportsBloomberg reports that Evonik is cooling on a potential acquisition bid for Ashland.
- UBS Raises Ashland Price Target to $88 From $80, Maintains Buy RatingUBS raised its price target on Ashland to $88 from $80 and kept its Buy rating.
- JP Morgan Maintains Overweight on Ashland, Raises Price Target to $82JP Morgan kept its Overweight rating and raised its price target on Ashland to $82.
- Ashland Inc. Reports Fourth Quarter and Full-Year Fiscal 2026 Financial ResultsQ4 sales were $498 million, up 4% year over year, with adjusted EPS of $1.12, and the company issued fiscal 2027 sales and EBITDA outlook.
- Ashland Sees FY2027 Sales $1.905B-$1.975B vs $1.929B EstAshland guided fiscal 2027 sales to $1.905B-$1.975B, with a midpoint of about $1.94B versus the $1.929B consensus.
- Ashland Q4 Adj. EPS $1.12 Misses $1.27 Estimate, Sales $498.000M Miss $501.813M EstimateAshland's Q4 adjusted EPS of $1.12 missed the $1.27 estimate, and sales of $498M missed the $501.8M estimate.
About Ashland Inc.
Ashland Inc. is a specialty chemicals company based in Wilmington, Delaware. It makes additives and ingredients, many derived from cellulose and other natural sources, for medicines, personal care products, coatings and industrial uses. Its products make up a small part of what a customer's finished product costs but matter a lot to how that product performs. In fiscal 2026, which ended in September, its sales were about $1.86 billion.
How it makes money
Ashland sells specialty ingredients to other manufacturers through four business units. Life Sciences supplies drug excipients (inactive ingredients that help deliver a medicine), nutrition and agricultural ingredients. Personal Care supplies ingredients for skin, hair and oral care products. Specialty Additives supplies thickeners and other additives for paints, coatings, construction and energy uses. Intermediates sells chemicals such as BDO and solvents. Life Sciences and Personal Care are its higher-growth units. The company also pays a quarterly dividend, currently about $0.42 per share.
What usually moves ASH
- Demand for drug ingredients and personal care products
- Paint, coatings and construction activity
- Raw material and energy costs, and pricing
- Plant operations (e.g., problems at its Hopewell site)
- Debt levels, asbestos and environmental liabilities, and an activist investor